

AMENDMENTS TO THE SPECIFICATION

Please amend the following paragraph inserted by Preliminary Amendment on page 1, after line 2 as follows:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. application serial number 09/299,016, filed April 26, 1999 (now ~~allowed~~ U.S. patent No. 6,280,731), which is a division of U.S. application serial number 08/836,982, filed June 27, 1997 (now U.S. patent No. 5,916,805), which is a 37 C.F.R. §1.371 continuation of PCT International Application PCT/JP95/02435, filed November 29, 1995.

Please insert the following paragraph at page 9 following line 12:

Brief Summary of the Invention

The present invention provides, in part, a pharmaceutical composition having antithrombotic efficacy containing a pharmaceutically acceptable carrier and a monoclonal antibody having the following properties:

- (a) the monoclonal antibody binds to human von Willebrand Factor; and
- (b) the monoclonal antibody inhibits binding between a monoclonal antibody produced by hybridoma and human von Willebrand Factor, wherein the hybridoma is selected from the group consisting of FERM BP-5248 (AJvW-2), FERM BP-5250 (AJvW-4) or a variant of the hybridoma.

Please amend the paragraph beginning on page 21, line 13 as follows:

Cells having been subjected to the fusion treatment are suspended in HAT medium, for example, ~~Dalbecco's~~ Dulbecco's modified Eagle's minimum essential medium (hereinafter abbreviated as "DMEM medium") containing hypoxanthine, aminopterin, thymidine, and 10% fetal bovine serum. The suspension is dispensed and poured into a 96-well microtiter plate or

the like, and cells are cultured at 37°C in 5% carbon dioxide so that only hybridomas are allowed to grow.

Please amend the paragraph beginning on page 24, line 20 as follows:

The medium for culturing the hybridoma includes, for example, a medium based on DMEM medium and further containing fetal bovine serum, L-glutamine, glucose, sodium pyruvate, 2-mercaptoethanol, and an antibiotic (for example, penicillin G, streptomycin, and gentamicin). The hybridoma of the present invention is usually cultured in the medium at 37°C for 2 to 4 days with a gas phase comprising 5% carbon dioxide and 95% air. Alternatively, the hybridoma is cultured for about 10 to 15 days in an abdominal cavity of ~~Balb/c~~ BALB/c mouse pretreated with 2,6,10,14-tetramethylpentadecane (for example, Pristane (trade name) produced by Sigma). Thus the monoclonal antibody is produced in an amount capable of being subjected to purification.